{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:06Z","timestamp":1784869326132,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study assessed the association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and the prevalence of diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We classified 2, 456 individuals with T2DM according to SGLT2 inhibitor treatment status. Propensity score matching (PSM) was implemented as the primary adjustment technique to achieve balance between groups on baseline demographics, laboratory values, comorbidities, and concurrent glucose-lowering agents. Additional propensity score weighting approaches were employed to examine the robustness of our findings, along with subgroup analyses and E-value calculations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among all participants, 399 (16.2%) had received SGLT2 inhibitors. Following PSM, each study arm comprised 398 patients. In the matched cohort, SGLT2 inhibitor use was associated with significantly increased odds of DPN (odds ratio 1.55; 95% confidence interval 1.17\u20132.05; p = 0.002). This association remained consistent across different propensity score methods, with odds ratios ranging from 1.55 to 1.7 (all p &amp;lt; 0.01). Subgroup analyses confirmed statistical significance, and E-value assessment supported the robustness of the observed effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2 inhibitor use was associated with a higher prevalence of DPN. Further prospective studies are warranted to establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1860467","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:27Z","timestamp":1784867007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The association between SGLT2 inhibitor use and diabetic peripheral neuropathy in type 2 diabetes: a cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuwei","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shijiazhuang","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Armed Police Forces Hospital of Shandong","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Hospital of Shijiazhuang","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","article-title":"IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050","volume":"41","author":"Duncan","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41582-024-01041-y","article-title":"The global and regional burden of diabetic peripheral neuropathy","volume":"21","author":"Savelieff","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04318-4","article-title":"Estimating the annual cost burden of diabetic peripheral neuropathy in the United States","volume":"90","author":"Borrelli","year":"2025","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-025-02241-5","article-title":"Diabetic neuropathy: cutting-edge research and future directions","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.003","article-title":"New perspectives in diabetic neuropathy","volume":"111","author":"Eid","year":"2023","journal-title":"Neuron"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12902-023-01526-9","article-title":"Lipid variability and risk of microvascular complications in patients with diabetes: a systematic review and meta-analysis","volume":"24","author":"Karimi","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B7","first-page":"47","article-title":"Australian foot health and disease in diabetes strategy 2030: Improving the foot health of people living with diabetes","volume-title":"Public Consultation Draft.","author":"Perrin","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13098-025-01790-w","article-title":"Dual-faced guardians: SGLT2 inhibitors\u2019 kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)","volume":"17","author":"Soliman","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e105114","DOI":"10.7759\/cureus.105114","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights","volume":"18","author":"Abdelfadil Elgazzar","year":"2026","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01828-2","article-title":"Innovative diabetes therapies and impact on peripheral and autonomic diabetic neuropathies: A state-of-the-art review","volume":"17","author":"Vekic","year":"2026","journal-title":"Diabetes Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12035-025-05457-5","article-title":"Targeting neurodegeneration with SGLT2is: from molecular mechanisms to clinical implications","volume":"63","author":"Asadinejad","year":"2025","journal-title":"Mol Neurobiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/ijpvm.ijpvm_5_23","article-title":"Neuroprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors (Gliflozins) on diabetes-induced neurodegeneration and neurotoxicity: A graphical review","volume":"15","author":"Gholami","year":"2024","journal-title":"Int J Prev Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00415-025-13566-3","article-title":"Peripheral nerve complications of weight loss associated with novel antihyperglycemic agents: a cohort study","volume":"273","author":"O'Gorman","year":"2025","journal-title":"J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.926717","article-title":"The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on diabetes-associated neuropathy: A systematic review and meta-analysis","volume":"13","author":"Kandeel","year":"2022","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1016\/s2468-2667(24)00250-0","article-title":"Diabetes in China part 1: epidemiology and risk factors","volume":"9","author":"Xu","year":"2024","journal-title":"Lancet Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.719356","article-title":"Gold standard for diagnosis of DPN","volume":"12","author":"Yu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1198\/jcgs.2011.10107","article-title":"Mice: multivariate imputation by chained equations","volume":"45","author":"Van Buuren","year":"2017","journal-title":"J Statistical Software"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14734","article-title":"Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes","volume":"24","author":"Bell","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i7.916","article-title":"Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind","volume":"12","author":"Infante","year":"2021","journal-title":"World J Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.diabres.2026.113334","article-title":"Treatment-induced neuropathy of diabetes: A comprehensive literature review","author":"Pantazopoulos","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27447","article-title":"Statins and the risk of polyneuropathy: A systematic review and two meta\u2010analyses","volume":"65","author":"Wannarong","year":"2021","journal-title":"Muscle Nerve"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081109","article-title":"Atypical diabetic neuropathies","volume":"390","author":"McCray","year":"2025","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/edm-19-0140","article-title":"Acute diabetic neuropathy following improved glycaemic control: a case series and review","volume":"2020","author":"Siddique","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101331","article-title":"The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial","volume":"48","author":"Liao","year":"2022","journal-title":"Diabetes Metab"},{"key":"B27","doi-asserted-by":"crossref","first-page":"12034","DOI":"10.3390\/ijms262412034","article-title":"Dapagliflozin Preserves Peripheral Nerve Structure and Reduces Neuropathic Damage in Streptozotocin-Induced Diabetic Peripheral Neuropathy","volume":"26","author":"\u021auc\u0103","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01858-8","article-title":"Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data","volume":"37","author":"Brockmeyer","year":"2024","journal-title":"J Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.014","article-title":"SGLT2 inhibitors to slow chronic kidney disease progression: A review","volume":"46","author":"Maxson","year":"2024","journal-title":"Clin Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2025.08.009","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of diabetic retinopathy: systematic review and meta-analysis","volume":"61","author":"Liang","year":"2025","journal-title":"Can J Ophthalmol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s10792-025-03768-z","article-title":"SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis","volume":"45","author":"Goodarzi","year":"2025","journal-title":"Int Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12883-025-04027-5","article-title":"Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report","volume":"25","author":"Chu","year":"2025","journal-title":"BMC Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2025.10.053","article-title":"Mechanism-driven multitarget therapeutics for diabetic peripheral neuropathy","volume":"590","author":"Kong","year":"2025","journal-title":"Neuroscience"},{"key":"B34","article-title":"Diabetes and the Nervous System: Linking Peripheral Neuropathy to Central Neurodegeneration","volume-title":"Preprints","author":"Hoque","year":"2025"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2020.05.001","article-title":"Bruns-Garland syndrome (diabetic amyotrophy) is associated with a rapid improvement in metabolic control","volume":"67","author":"Sim\u00f3-Servat","year":"2020","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99918","article-title":"Treatment-induced diabetic neuropathy: A case report on multimodal pain management in a young patient with type I diabetes","volume":"17","author":"Lee","year":"2025","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-025-02635-6","article-title":"Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer","volume":"29","author":"Terashita","year":"2025","journal-title":"Clin Exp Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.2025.14136","article-title":"Dapagliflozin-Induced Severe Hypernatremia in a Non-Communicative Stroke Patient on Enteral Feeding","volume":"2025","author":"Jang","year":"2025","journal-title":"Korean J Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1860467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:29Z","timestamp":1784867009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1860467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1860467"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1860467","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1860467"}}